Phase I Trial Evaluating Genetically Modified Autologous T Cells Expressing a T-Cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Squamous Cell Non-small Cell Lung Cancer or Head and Neck Squamous Cell Carcinoma

Trial Profile

Phase I Trial Evaluating Genetically Modified Autologous T Cells Expressing a T-Cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Squamous Cell Non-small Cell Lung Cancer or Head and Neck Squamous Cell Carcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs IMA-201 (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
  • Indications Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms ACTengine
  • Sponsors Immatics US
  • Most Recent Events

    • 26 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 05 Sep 2017 Planned initiation date changed from 31 Aug 2017 to 30 Sep 2017.
    • 16 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top